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priate management. This study was performed to explore how different methods
stratify the risk of CVD and how the awareness of CVD risk impacts its manage-
ment in hypertensive patient. METHODS: A prospective, multi-center observa-
tional studywas conducted in hypertensive patients aged 40 years in Korea. CVD
risk was assessed using the clinical algorithm (the National Cholesterol Education
Program-Adult Treatment Panel III guideline) and carotid ultrasound (CUS). Physi-
cians’ CVD risk management patterns were assessed through chart review. Pa-
tients also completed a questionnaire before and 6months after CVD risk assess-
ment to determine self-reported behavioral changes. RESULTS: Among 294 (male
65%, 618 years), 14,9, 77.8 and 7.3% patients were determined to have low, mod-
erate and high CV risk by CUS and 49.0 and 51.0% patients were low and high risk
by clinical algorithm, respectively. Among 273 patients classified as having low-to-
moderate CV risk by the clinical algorithm, approximately half of patients (51%,
138/273) were redefined as high risk by CUS. For the high-risk comparing to the
low-risk patients based on CUS, physicians set more lowered target goals for the
management of hypertension (25.8 vs. 3.6% of physicians, P0.001), LDL-choles-
terol (51.6 vs. 23.6% of physicians, P0.001) and more changed the intensities of
anti-hypertensive agent (4.9 vs. 1.2% of physicians, P0.047). Patients reported
higher rates of smoking cessation, dietary changes (reduced dietary sodium), and
increased medication compliance at 6month comparing to the baseline (P0.05,
respectively). CONCLUSIONS: This study shows that there is a significant differ-
ence in CVD risk level between clinical algorithm and CUS. However, proactive
awareness of CV risk had major effects on physician and patient behaviors in CVD
risk management.
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OBJECTIVES: Evaluating the burden of a disease is a new way of measuring its
impact on the lives of sufferers, as it takes into account all the problems caused by
the illness. The ABC-V questionnaire was created and published in 2010 (Phlebol-
ogy, 2010-25:280-285).METHODS: It was administered to a population under treat-
ment with phlebotonic drugs (Ruscus aculeatus, Hespéridine méthyl chalcone,
ascorbic acid) RESULTS: Sixty-five subjects were monitored for 56 days, average
age 4716.7, gender: 60% women, with an average BMI of 24.763,95. At inclusion
and before treatment, the burden score was 32.817.6. No difference was observed
according to gender (the male score was 33.6 20.2, the female 32.315.48 p0.4),
to age (35.2  12.4 in those older than 55 vs 31.1520.2 in the younger age braced
(p0.2); There was a difference, however, in the ABC-V score dependent on sport
activity: 36.05 vs 27,68(p0.02) On days 28 and 56, the burden score was 22.613.9
and 19.613.8 respectively. The burden is therefore observed to have significantly
and statistically reduced. The quantity of effect has been measured, and the bur-
den is 27% reduced on the day 28 and 40% on day 56. Aside from averages, a
reduction in burdenwas observed in nearly 93% of subjects. For 68% of subjects the
reduction was greater than 30% by the 56th day. Greater reduction of burden was
observed in subjects who took regular exercise, vs those who did not (41% vs 38%)
and under 50 vs over 50 (47% vs 31%) The scores that improved the most were:
treatment by GP (58%), daily life (52%) and psychological impact (54%)
CONCLUSIONS: The ABC-V burden questionnaire was created and validated in
2010 (psychometric and cognitive debriefing). This study has demonstrated and
confirmed its sensitivity to change. It is available in French, English, Italian and
Spanish.
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OBJECTIVES: Tests of exercise capacity and quality of life (QOL) questionnaires are
used to predict outcomes in heart failure (HF) patients. The short performance
physical battery (SPPB) and Ferrans and Power’s quality of life index (QLI) are sim-
ple, free tests commonly used in geriatric and oncology patients, but data on their
use in cardiovascular diseases is limited. We sought to assess their utility in ad-
vanced HF patients.METHODS: Ten patients with advanced HF scheduled for ven-
tricular assist device implant were enrolled in this prospective, observational
study. Multiple exercise capacity tests including maximal cardiopulmonary stress
testing (CPX), 6 minute walk (6MWT), shuttle walk test (SWT), and SPPB were per-
formed. Minnesota Living With Heart Failure (MLWHF) questionnaire, SF-36 v2™,
and QLI were administered. Cardiac output was measured non-invasively by acet-
ylene rebreathing. Data were reported in meanSD. Pairwise correlations were
calculated between exercise capacity tests and QOL questionnaires. RESULTS:
Mean age was 62.18.6 years. The mean CPX duration was 5.62.9 minutes and
CPX respiratory exchange ratio (RER) was 1.20.2. The 6MWTwas 290137m, SWT
distance was 16797 m, and SPPB score was 7.7  2.6. MLWHF score was 6915,
mean SF-36 Physical Component Score (PCS) was 3010, SF-36 Mental Component
Score was 4212, and QLI was 19.24. CPX maximal cardiac output was 5.83 at
rest and 8.45.9 L/min at peak exercise. SPPB score showed a trend towards posi-
tive correlation with 6MWT (r0.6, p0.06), SF-36 PCS (r0.55, p0.096) and a
negative correlation with MLWHF score (r -0.71, p0.01). QLI was positively cor-
related with CPX RER (r0.7, p0.05), 6MWT (r0.7, p0.005), SWT distance
(r0.79, p0.03), and SF-36 PCS (r0.7, p0.01). CONCLUSIONS: SPPB and QLI cor-
related well to more laborious and technically demanding exercise capacity tests
and generic QOL indices in advanced HF patients. Additional evaluation in a
broader population of heart failure patients is needed.
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OBJECTIVES: To compare clinicians’ and patients’ views of post-stroke spasticity
(PSS) symptoms and their impact on health-related quality of life (HRQoL).
METHODS: Interviews were conducted with 13 clinicians specializing in the treat-
ment of PSS. Emergent themes from these interviews were compared with the
findings from 6 patient focus groups involving 59 patients. RESULTS: Clinicians
described altered muscle tone and spasticity as distinct manifestations of upper
motor neuron syndrome but suggested that patients do not distinguish between
the two. Clinicians perceived patients to view spasticity as muscle tightness/stiff-
ness that affects limb positioning, posture, and function, with patient values and
coping strategies influencing the degree to which PSS impacts various domains of
their lives. Existing HRQoL measures were thought to be too general and to over-
look specific consequences associated with PSS. Patients described PSS in terms of
movement difficulties, and not muscle characteristics. Specifically, patients char-
acterized PSS as an inability to direct armmovements, position the hand, and grasp
objects in the upper limbs; and, as an inability to walk, maintain balance, and
minimize the risk of falls in the lower limbs. Ten HRQoL domains were found to
fully represent the effects of PSS on individual well being: symptom impact, phys-
ical function, activities of daily living, ambulation and mobility, ambulation risk,
social function, social support, loss of role function, appearance, and adaptive
resiliency. CONCLUSIONS: While clinicians and patients generally agreed on the
functional areas affected by PSS, clinicians tended to focus on diagnostic features
of excess muscle tonicity and spasm whereas patients concentrated on the com-
plex psychosocial effects of PSS - particularly the effects of disability on their sense
of self and personal relationships. An understanding and assessment of the com-
plex ways that PSS impacts patients’ lives has clinical relevance, particularly in
terms of screening for disabling PSS and treatment decisions.
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OBJECTIVES: To assess the effect of secondary preventive measures on the Health
Related Quality of Life (HRQoL) of myocardial infarction patients. METHODS: The
Medical Expenditure Panel Survey (MEPS) data from 2004 to 2008 were used to
conduct a retrospective longitudinal study which included adults  18 years with
myocardial infarction. The lifestyle modifications considered were smoking cessa-
tion, regular exercise and weight control. Pharmacotherapy was defined as the use
of aspirin, beta-blockers, statins and ACEI/ARBs. HRQoL was determined on the
basis of the SF-12 survey instrument. Two multiple linear regression models for
physical component summary (PCS) and mental component summary (MCS)
scores were conducted. The primary independent variables included the second-
ary preventive measures. The other predisposing, enabling and need variables
were identified based on the Andersen Behavior Model. A p-value of 0.05 was
considered to be statistically significant. RESULTS: Non-smokers had a signifi-
cantly better MCS score as compared to smokers (  2.88; CI: 0.90 – 4.85; p 
0.0053). Regular exercise was significantly associated with improvement in PCS
(  3.28; CI: 1.91 – 4.64; p  0.001) and MCS ( 1.83; CI: 0.23 – 3.42; p  0.0255)
scores whereas statin use was associated with an improvement in the MCS ( 
3.31; CI: 1.80 – 4.83; p  0.001). Use of ACE/ARB, beta-blocker or aspirin and normal
BMI, however, were not associated with improvement in HRQoL. CONCLUSIONS:
Lifestyle modifications like smoking cessation and exercise combined with regular
use of statins will help to improve HRQoL in patients with myocardial infarction.
Thus these measures should be aggressively promoted among myocardial infarc-
tion patients.
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OBJECTIVES: Comorbidities in Heart Failure (HF) patients are highly prevalent,
adversely affecting health related quality of life (HRQoL). Health related quality of
life-comorbidity index (HRQoL-CI) has been recently developed to risk adjust
HRQoL. The aim of this study was to compare the performance of HRQoL-CI with
Charlson and Elixhauser measures in predicting HRQoL in HF patients.METHODS:
The Medical Expenditure Panel Survey 2002-2008 data was used for this retrospec-
tive cross-sectional study. All adults (age 18 years) diagnosed with HF were in-
cluded in the study. International Classification of Disease, 9th Revision, Clinical
Modification and Clinical Classification Codes were used to identify HF patients, as
well as to construct different risk adjustment measures (D’hoore adaptation of
Charlson, Elixhauser and HRQoL-CI). HRQoL is documented in MEPS using short
form health survey (SF-12), with physical component score (PCS) and mental com-
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